Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
暂无分享，去创建一个
A. Hauschild | D. Schadendorf | K. Flaherty | A. Ribas | J. Schachter | C. Garbe | M. Mandalà | H. Gogas | P. Rutkowski | J. Grob | B. Karaszewska | V. Chiarion-Sileni | G. Long | C. Robert | J. Haanen | C. Lebbé | J. Legos | A. Mackiewicz | D. Stroiakovski | P. Nathan | B. Mookerjee | C. Dutriaux | E. Levchenko | M. Kaper | M. Davies | Ying Zhang